Arcus Biosciences, Inc. (RCUS) Research

Arcus Biosciences, Inc. is a U.S.-based, clinical-stage biopharmaceutical company dedicated to discovering and commercializing innovative cancer therapies. Its pipeline features several promising drug candidates: Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, is currently in Phase 1b/2 clinical trials. Zimberelimab, an anti-PD-1 antibody, is being evaluated as a monotherapy in Phase 1b studies. Another key asset is Domvanalimab, an anti-TIGIT monoclonal antibody, undergoing Phase 2 development for first-line metastatic non-small cell lung cancer when administered with Zimberelimab. The company is also developing Quemliclustat, a small-molecule CD73 inhibitor, in Phase 1/1b studies for the initial treatment of metastatic pancreatic cancer. AB521, an oral small molecule HIF-2a inhibitor, is in Phase 1 trials for patients with von Hippel-Lindau disease. Arcus actively collaborates with other entities to advance its programs. It has a clinical development partnership with Strata Oncology, Inc. to assess Zimberelimab. Furthermore, a significant collaboration with AstraZeneca and BVF Partners L.P. is underway for a registrational Phase 3 clinical trial, testing Domvanalimab (an experimental anti-TIGIT antibody) alongside Imfinzi (durvalumab) in patients with unresectable Stage III non-small cell lung cancer. Additionally, Arcus holds licensing agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics for the development of an anti-CD39 antibody targeting various cancers. Incorporated in 2015, the company's corporate headquarters are located in Hayward, California.

Open Arcus Biosciences, Inc. (RCUS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.